DeepMed Research

Rogel Cancer Center: University of Michigan

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1991-01-01

Employees: -

Market Cap: -

Website: http://www.rogelcancercenter.org

Clinical Trials

Expansion Trial for Axitinib In Head And Neck Cancer

Phase 2

Completed

Conditions: Squamous Cell Carcinoma of the Head and Neck

Interventions: Drug: Axitinib

First Posted Date: 2016-05-05

Last Posted Date: 2021-05-05

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 29

Registration Number: NCT02762513

Locations: 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

Clinical Outcomes, Nutritional Status, Exercise and Psychosocial Factors in Pediatric Hematopoietic Cell Transplant

Completed

Conditions: Malnutrition
Obesity

First Posted Date: 2016-04-12

Last Posted Date: 2024-01-25

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 55

Registration Number: NCT02734797

Locations: 🇺🇸
University of Michigan Health System, Ann Arbor, Michigan, United States

Pilot Study of Pazopanib With Low Fat Meal (PALM) in Advanced Renal Cell Carcinoma

Early Phase 1

Completed

Conditions: Carcinoma, Renal Cell

Interventions: Drug: Pazopanib
Other: Low Fat Diet

First Posted Date: 2016-04-06

Last Posted Date: 2019-06-10

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 16

Registration Number: NCT02729194

Locations: 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

Prospective Study Evaluating the Use of PROSPECT to Reduce Insomnia in Patients With Early Stage Breast Cancer

Not Applicable

Terminated

Conditions: Breast Cancer
Insomnia

Interventions: Behavioral: PROSPECT

First Posted Date: 2016-03-18

Last Posted Date: 2017-09-08

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 4

Registration Number: NCT02712437

Locations: 🇺🇸
Unvisterity of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

Imaging Biomarker for Early Detection of Treatment Efficacy During Breast Cancer Neoadjuvant Chemotherapy

Early Phase 1

Completed

Conditions: Breast Cancer

Interventions: Device: Diffusion weighted MRI

First Posted Date: 2016-02-10

Last Posted Date: 2016-02-11

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 25

Registration Number: NCT02679586

Locations: 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Phase 1

Withdrawn

Conditions: Chronic Lymphocytic Leukemia
Lymphoma, Small Lymphocytic

Interventions: Drug: Pacritinib
Drug: Ibrutinib

First Posted Date: 2016-02-09

Last Posted Date: 2017-09-06

Lead Sponsor: University of Michigan Rogel Cancer Center

Registration Number: NCT02677948

Locations: 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

A Phase II Trial Evaluating WNT974 in Patients With Metastatic Head and Neck Squamous Cell Carcinoma

Phase 2

Withdrawn

Conditions: Squamous Cell Carcinoma, Head And Neck

Interventions: Drug: WNT974

First Posted Date: 2016-01-07

Last Posted Date: 2016-09-30

Lead Sponsor: University of Michigan Rogel Cancer Center

Registration Number: NCT02649530

Locations: 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma

Phase 1

Completed

Conditions: Hodgkin's Lymphoma
Lymphoma, Non-Hodgkin

Interventions: Drug: Bortezomib
Drug: Ruxolitinib

First Posted Date: 2015-11-24

Last Posted Date: 2021-12-20

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 15

Registration Number: NCT02613598

Locations: 🇺🇸
University of Michgan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

Pilot Study of Biomarkers and Cardiac MRI as Early Indicators of Cardiac Exposure Following Breast Radiotherapy

Completed

Conditions: Breast Cancer

Interventions: Procedure: Research Cardiac MRI
Procedure: Biomarkers

First Posted Date: 2015-07-10

Last Posted Date: 2019-07-30

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 23

Registration Number: NCT02494453

Locations: 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States

A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer

Not Applicable

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Radiation: Response-driven Adaptive Radiation Therapy
Drug: Carboplatin
Drug: Paclitaxel
Device: FDG-PET
Device: V/Q SPECT
Drug: Durvalumab

First Posted Date: 2015-07-09

Last Posted Date: 2023-08-31

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 49

Registration Number: NCT02492867

Locations: 🇺🇸
VA Ann Arbor Healthcare System, Ann Arbor, Michigan, United States
🇺🇸
University of Michigan Cancer Center, Ann Arbor, Michigan, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy